RNAimmune is a biotechnology startup specializing in messenger RNA (mRNA) technology, leveraging over two decades of expertise to develop innovative medical solutions for oncology, immunology, and infectious diseases. The core of RNAimmune's proprietary technology involves using mRNA as a data carrier, instructing the human body to produce proteins that combat various diseases. Their therapeutic focus includes developing prophylactic vaccines to enhance immune responses against serious infectious diseases, individualized neoantigen-based vaccines for cancer treatment, and mRNA-based therapeutics for rare diseases. The company is actively advancing its pipelines, which emphasize mRNA vaccines targeting cancer and respiratory viruses, as well as mRNA cancer immunotherapies.

To optimize their mRNA applications, RNAimmune has established a synthetic biology-based design platform, enhanced by artificial intelligence, to create more effective mRNA sequences that elicit robust immune responses. Additionally, they have developed proprietary delivery methods, including lipid nanoparticle (LNP) formulations and Polypeptide Lipid Nanoparticle (PLNP) carriers, which facilitate the efficient delivery of mRNA into cells. Their advancements in antigen engineering and self-amplifying mRNA technologies further strengthen the potency and duration of their treatments, positioning RNAimmune at the forefront of mRNA-based therapeutic development.

United States

At RNAimmune, we use mRNA technology to help people live full and healthy lives. Our primary focus is development of vaccines against cancer and respiratory viruses. Our expertise in design and production of mRNA vaccines is supported by research and development efforts toward novel lipids, targeted delivery and antigen engineering. 

We collaborate with the world for the health of everyone.

RNAimmune

Company Details